2-Sulfanilamidothiazole

When the target final dosage form is a sterile injectable solution or soluble powder for reconstitution, the free-acid form of 2-Sulfanilamidothiazole is not directly applicable due to its limited aqueous solubility—approximately 0.6 mg/mL at 25°C. The conversion into the corresponding sodium salt dihydrate is therefore executed as an in-house intermediate step within API manufacturing suites classified as Grade D (ISO 8) under Annex 1 of the EU GMP Guide, followed by terminal sterilization. The reaction is performed in a glass-lined reactor (DIN 28136) purged with pharmaceutical-grade nitrogen. A suspension of the micronized free acid (particle size D₉₀ ≤ 20 µm) in Water for Injection at a 1:8 (w/w) ratio is heated to 58–62°C, and 30% w/w sodium hydroxide solution is dosed under cascade pH control at a rate of 0.3–0.5 kg/min per 200 kg batch mass until a steady-state pH of 8.6–9.0 is reached. A transient pH overshoot beyond 9.3, even for 90 seconds, triggers a measurable hydrolysis pathway: the sulfonamide bridge is cleaved, generating sulfanilamide and 2-aminothiazole fragments, which are recorded as related substances by the HPLC method specified in USP <621> Chromatography, using a C18 column (4.6 × 150 mm, 5 µm) and a phosphate buffer–acetonitrile mobile phase (75:25 v/v) with detection at 254 nm. The neutralized solution is treated with activated carbon (vegetal origin, acid-washed, 0.4% w/w of batch mass) at 70°C for 45 minutes to reduce bacterial endotoxins below 0.25 EU/mg, a limit harmonized with the USP <85> Bacterial Endotoxins Test. Carbon retention is achieved through a dual-stage filtration train: a 0.45 µm polyethersulfone capsule followed by a 0.22 µm sterilizing-grade PVDF membrane. The clarified filtrate enters a lyophilization cycle in a shelf-type freeze dryer (shelf surface area ≥ 10 m²) with a product fill depth of 15 ± 2 mm. Primary drying is conducted at a shelf temperature of −25°C and a chamber pressure of 0.08–0.12 mbar for 22 hours, followed by ramp to 35°C over 6 hours for secondary drying, yielding a stoichiometric hemihydrate with a residual moisture specification limited to 1.5–3.0% by Karl Fischer coulometry (USP <921>). This intermediate product is milled under nitrogen in a conical sieve mill equipped with a 300 µm screen and packed in double polyethylene liners inside aluminum-laminated foil bags under vacuum. The batch release criteria are aligned with the harmonized monograph “Sulfathiazole Sodium” of the European Pharmacopoeia (10.5), which mandates an assay of 99.0–101.0% on the dried basis, clarity and color of a 1 in 20 aqueous solution, loss on drying ≤ 5.0%, heavy metals ≤ 20 ppm, and a sulfanilamide impurity limit ≤ 0.5%.

The stoichiometric requirement for sodium hydroxide is 1.02–1.05 mol per mole of 2-Sulfanilamidothiazole, with the slight excess consumed during carbon treatment and neutralized by trace acidic surface oxides. The residual free alkali is back-titrated to adjust the final injectable formulation pH to 8.0–8.5, compatible with the buffering capacity of citrate or phosphate vehicles. Terminal sterilization of the reconstituted solution is accomplished by autoclaving at 121°C for 15 minutes (F₀ ≥ 12 minutes), with the sterilized product meeting the requirements of USP <1> Injections and 21 CFR 211.167. The final commercial presentation is a 30% w/v Sulfathiazole Sodium Injection in 100 mL molded glass vials, used extensively in poultry and swine production systems under veterinary prescription, where dosing accuracy is verified against USP <905> Uniformity of Dosage Units. A recognized operational bottleneck occurs during filtration: the viscous carbon-loaded liquor at ∼15 cP demands a transmembrane pressure gradient maintained below 1.2 bar to avoid premature membrane blinding and product loss in the filter cake, a constraint that limits batch throughput to roughly 3.5 batches per 24-hour cycle on a 1 m² pre-filtration skid.

Medicated Feed Premix Processing: Granulation Endpoint and Cross-Contamination Controls

In poultry and swine production, 2-Sulfanilamidothiazole is formulated as a medicated premix intended for incorporation into complete feed at a veterinary feed directive level, with inclusion rates established under 21 CFR 558.128 and the corresponding EU Commission Regulation (EU) No 37/2010, which assigns sulfathiazole an MRL of 100 µg/kg in muscle, liver, and kidney of porcine and avian species, with a mandatory withdrawal period varying between 7 and 14 days depending on the national authority. A typical premix concentrate carries an activity of 22 g sulfathiazole base per kilogram of carrier ( 2.2% w/w), and the final diluted feed contains between 100 and 200 ppm of the active compound. The manufacturing process is governed by EU GMP Part II (ICH Q7) for APIs used in veterinary medicinal products and is subject to the carry-over limit calculations defined in EU Regulation (EC) No 183/2005 on feed hygiene.

Carrier selection is critical to blend uniformity: a calcium carbonate-montmorillonite composite with a tapped bulk density of 1.1–1.3 g/cm³ and a specific surface area of 8–12 m²/g (BET method, ISO 9277:2022) is used to adsorb the micronized sulfathiazole powder (D₅₀ ≈ 5 µm). Premix granulation is performed in a high-shear mixer-granulator equipped with a double-walled jacketed vessel (bowl volume 600 L), where the dry blend is wetted with a binder solution of pregelatinized starch (5% w/w in purified water) sprayed at a rate of 2 L/min. The end-point is determined by power consumption monitoring on the main impeller: a plateau at 18–22 kW for a 300 kg working load corresponds to a granule size distribution in the range 200–800 µm with a fines fraction (<100 µm) held below 12% by sieve analysis (ASTM E11). Subsequently, the wet mass is discharged through a 4 mm screen into a fluid-bed dryer operating with an inlet air temperature of 70 ± 5°C and an air velocity of 1.5 m/s to achieve a loss on drying of 1.8–2.5% (USP <731> infrared balance). Dried granules are sized over an oscillating sieve with 800 µm aperture and blended with 0.5% w/w magnesium stearate as a flow aid for subsequent bagging in 25 kg antistatic polyethylene-lined paper sacks. Cross-contamination abatement relies on a validated cleaning-in-place protocol: sequential rinses of 0.1 M hydrochloric acid and 0.05 M sodium hydroxide at 60°C, verified by surface swab spectrophotometric analysis at 260 nm with an acceptance threshold of 0.5 µg/cm².

The final premix is homogenized into complete feed using a horizontal ribbon mixer with a coefficient of variation (CV) ≤ 10% as per ISO 6497 requirements, and each production lot is sampled at 10 predetermined points to confirm label claim consistency. Downstream, the medicated feed may be pelleted through a ring die pellet mill conditioned with steam at 80°C for 20–30 seconds; pellet durability, measured by the Pfost Durability Index (PDI), must remain > 92%. Thermally induced degradation of sulfathiazole under these conditions is buffered by the calcium carbonate carrier, which maintains a microenvironment pH of 7.8–8.2 and limits free thiazole formation to ≤ 0.8% of declared potency. Terminal products include Type B and Type C medicated feeds for broilers, starter pigs, and lactating sows, complying with the potency limits of ±5% of the formulation target stated in 21 CFR 558.3.

Can a Compounded Sulfathiazole Ointment Satisfy Current GMP Requirements for Niche Veterinary Indications?

Topical formulations containing 5% w/w 2-Sulfanilamidothiazole in a hydrophobic ointment base are still prepared by veterinary compounding pharmacies and a limited number of licensed manufacturers for the management of superficial pyogenic infections in equine and ovine practice, where commercial ampicillin or tetracycline alternatives face resistance or supply discontinuity. The compliance framework draws upon USP <795> Pharmaceutical Compounding—Nonsterile Preparations and USP <797> Pharmaceutical Compounding—Sterile Preparations where open wounds demand a sterile vehicle, though most ointments are classified as nonsterile. A conventional quality target product profile specifies an active ingredient assay of 90.0–110.0% and a content uniformity acceptance value (AV) ≤ 15 per USP <905>. The base is typically a blend of white petrolatum (USP), mineral oil, and 5–8% w/w white wax, chosen for its occlusivity and chemical inertness toward the primary amine and sulfonamide moieties.

Manufacturing is conducted in a planetary mixer (bowl capacity 50–200 kg) at 45–50°C, where the sulfathiazole powder, previously sieved through a 100 µm screen to eliminate agglomerates > 150 µm, is gradually incorporated into the molten base. Shear is maintained at 30–40 rpm paddle speed for 25–30 minutes until microscopic examination (×100 magnification) confirms no crystal aggregates above 50 µm. The absence of crystal habit change—specifically, conversion from the stable Form II polymorph to Form I, which exhibits a lower melting point (202°C vs. 207°C) and accelerated release of free thiazole—is verified by differential scanning calorimetry (ISO 11357-1:2023) with a heating rate of 10°C/min under nitrogen. Filling into collapsible aluminum tubes (internal epoxy phenolic lining per EN 13046) is performed at a temperature not exceeding 42°C to prevent precipitation of the active on cooling, and the sealed tubes undergo a leak test by submersion in 0.05% methylene blue solution under vacuum (−0.8 bar). Stability studies following ICH Q1A(R2) at 40°C/75% RH for 6 months show that the addition of 0.1% w/w butylated hydroxytoluene (BHT) reduces oxidative discoloration, measured as the increase in absorbance at 450 nm (1 cm pathlength) by 60% relative to the unprotected control.

The primary operational limitation in commercial scale-up is the pronounced tendency of sulfathiazole to undergo electrostatically driven interparticle cementation during storage at relative humidity > 55%, necessitating environmental controls of 40 ± 5% RH in dispensing and blending suites. Furthermore, direct contact with iron oxide pigments, occasionally requested for wound camouflage in equine products, is contraindicated because ferric ions catalyze sulfonamide oxidation, generating yellow-brown degradation products detectable by thin-layer chromatography (USP <221>, silica gel G, chloroform-methanol-water 80:20:2). The finished ointment is supplied in 15 g, 30 g, and 500 g dispensing containers labeled for veterinary use only, with a shelf-life of 24 months when stored below 25°C.

When a laboratory establishes traceability of sulfonamide residue analysis in tissues, milk, or honey according to Commission Implementing Regulation (EU) 2021/808 or the FDA CVM GFI #118 multi-residue methods, the certified reference material (CRM) of 2-Sulfanilamidothiazole must be characterized with a level of metrological rigor that extends well beyond that of an industrial intermediate. The production sequence for a 100 g lot of primary CRM, intended for calibration of LC-MS/MS transitions m/z 256.0 → 156.0 (quantifier) and m/z 256.0 → 108.0 (qualifier), begins with preparative recrystallization from a 50:50 v/v ethanol-water mixture at 60°C with a cooling rate of 0.5°C/min to yield needle-shaped crystals of > 99.9% chromatographic purity. The material is dried in a vacuum oven at 105°C and 5 mbar for 16 hours to constant weight, handled exclusively in a glove box under argon where the dew point is maintained below −40°C. Purity assignment is performed via mass balance approach: organic impurities are quantified by HPLC-DAD (ISO 22854:2021, extended with in-house validation for resolution ≥ 3.0 between sulfathiazole and its main impurity sulfanilamide), inorganic impurities by sulfated ash (USP <281>), residual solvents by headspace GC-FID (USP <467>, residual ethanol ≤ 50 ppm), and water content by Karl Fischer coulometry. The combined uncertainty budget, calculated in compliance with the Guide to the Expression of Uncertainty in Measurement (GUM, JCGM 100:2008), is reported as 0.25% (coverage factor k=2) for the assigned mass fraction of 99.86 ± 0.50%.

The certified value is anchored to the USP Sulfathiazole RS or the Ph.Eur. Chemical Reference Substance (CRS) via a direct comparison protocol under ISO 17034:2016 clauses 7.2 to 7.11. Homogeneity assessment requires 15 randomly selected units of 100 mg sealed in amber glass vials (Type I borosilicate, pH neutral, ISO 4802-1) to be tested by the primary HPLC method with ANOVA analysis confirming a between-bottle standard deviation ≤ 0.05%. Short-term stability under transport conditions is verified at 60°C for 14 days with a change in assigned purity constrained to ≤0.1%. Long-term stability at −20°C is monitored over 36 months using the isochronous approach, and the shelf-life is re-estimated by linear regression with a prediction interval at 95% confidence. This CRM is then employed to validate sulfonamide detection methods in matrices such as bovine muscle and liquid whole egg, where the CCα (decision limit) for sulfathiazole must not exceed 10 µg/kg in accordance with ISO 15118:2019 guidelines for screening methods in food safety testing. End-use vials are accompanied by a certificate complying with ISO Guide 31:2015, with the designated product code typically appearing as “CRM-2SFTZ-100MG” in catalogues serving National Reference Laboratories and accredited enforcement bodies.

Building Block for Sulfonamide-Thiazole Conjugate Synthesis in Medicinal Chemistry Programs

The thiazole ring and the para-aminophenylsulfonamide terminus of 2-Sulfanilamidothiazole present two nucleophilic sites that are exploited in early-stage lead optimization at contract research organizations (CROs) and university medicinal chemistry labs for the construction of focused libraries aimed at carbonic anhydrase isoforms, dihydropteroate synthase mutants, or bacterial efflux pump inhibition. In these synthetic workflows, the substance is employed as a 95–99% purity raw material, typically supplied in quantities of 50 g to 1 kg in amber HDPE bottles with a desiccant liner, with procurement specifications aligned with the ISO 9001:2015 quality system of the vendor. The deprotonation of the sulfonamide NH with sodium hydride (60% dispersion in mineral oil, washed with anhydrous hexane) in dry N,N-dimethylformamide (DMF) at 0–5°C generates a sulfonamide anion that can be trapped with substituted benzyl halides to give N4-functionalized derivatives; the conversion is monitored by TLC (silica, ethyl acetate-hexane 1:1, R_f of product ≈ 0.45) and requires a 1.1 equivalent excess of electrophile to drive the reaction to completion within 4 hours.

Alternatively, the primary amino group undergoes diazotization with sodium nitrite in concentrated hydrochloric acid at −5 to 0°C to yield a diazonium salt that is coupled with electron-rich arenes (e.g., N,N-dimethylaniline) to produce azo dyes with absorption maxima in the region 420–480 nm; this synthetic pathway is employed for the preparation of haptens used in enzyme-linked immunosorbent assay (ELISA) development for sulfonamide detection. A particularly sensitive parameter in the diazo coupling is the stoichiometric ratio: an excess of nitrite beyond 1.02 equivalents generates nitrosation side-products that deteriorate the hapten-carrier protein coupling efficiency, as measured by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) monitoring of a bovine serum albumin conjugate. The primary analytical release for this grade of material relies on HPLC-UV (column: 4.6 × 250 mm, 5 µm C18; eluent: 0.1% trifluoroacetic acid in water/acetonitrile gradient 95:5 to 5:95 over 30 min) coupled with ¹H NMR (400 MHz, DMSO-d₆) where the diagnostic singlet of the thiazole H4 proton appears at δ 6.85, and the doublet of the aromatic protons ortho to the sulfonamide is observed at δ 7.34 (J = 8.6 Hz). Any batch containing > 0.5 area% of the condensation dimer—formed by self-reaction during prolonged storage above 30°C—is rejected and re-purified by flash column chromatography (silica gel 60 Å, 230–400 mesh, eluting with methanol-chloroform 5:95).

Notably, the use of 2-Sulfanilamidothiazole as a synthetic intermediate for the preparation of silver sulfathiazole (for burn wound management under the regulatory framework of 21 CFR Part 314 OTC drug review) demands an iron content below 5 ppm because residual iron forms a grayish precipitate with chloride ions in the wound exudate, compromising the aesthetic and clinical acceptance of the cream. This specification is enforced through inductively coupled plasma optical emission spectrometry (ICP-OES, ISO 11885:2009) against a multi-element standard. Process-scale synthesis of the silver salt is conducted in a 50 L jacketed glass reactor under dim red light with slow addition of the sulfathiazole sodium solution to silver nitrate solution at a rate of 0.5 L/h, generating a fine white precipitate that is washed free of excess nitrate, dewatered by centrifugation (11,000 g, 15 min), and dried in vacuo at 40°C in the dark to an assay of ≥ 98.0%. The final product type for the catalog chemical market is a 1 g or 5 g screw-cap vial bearing a batch-specific certificate of analysis, or kilogram-scale jacketed bags in compliance with ECHA REACH registration requirements when imported into the European Economic Area.